Bliss GVS open offer: IDC backs ₹299 for 26% in 2026

What the recommendation is, and why it matters

Bliss GVS Pharma Limited’s Committee of Independent Directors (IDC) has recommended the open offer made by Anupam Rasayan India Limited to public shareholders. The offer is to acquire up to 26% of Bliss GVS’s expanded voting share capital at an offer price of ₹299 per share. The recommendation was issued under Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SEBI SAST). The IDC said it reviewed the pricing parameters and found the offer price to be “fair and reasonable” under the regulations. This matters because an IDC recommendation is a key disclosure for minority shareholders when deciding whether to tender shares. The committee also highlighted a practical issue for investors: the prevailing market price at the time cited in the disclosure was higher than the offer price. That gap can influence tendering decisions, especially for shareholders focused on near-term price realisation.

Open offer terms: size, price, and total consideration

The open offer seeks to purchase up to 2,77,26,848 fully paid-up equity shares of Bliss GVS Pharma. This represents 26.00% of the expanded voting share capital, as disclosed in the company’s intimation. The offer price is set at ₹299.00 per share. Based on the disclosed calculation, the total consideration aggregates to ₹8,290,327,552, which is about ₹829.03 crore. The disclosure identifies Anupam Rasayan India Limited as the acquirer, along with Mates Visa Consultancy Private Limited as the person acting in concert (PAC). SBI Capital Markets Limited is the manager to the open offer. The company’s filing also provides an investor contact reference with SBI Caps for the open offer.

Why the IDC said ₹299 is “fair and reasonable”

The IDC met on July 22, 2026 at 11:30 a.m. IST to consider the open offer and the applicable pricing parameters. It concluded that the offer price of ₹299 per share represents the highest of the applicable parameters under SEBI SAST rules. One of the disclosed reference points is the volume weighted average market price (VWAP) of ₹247.55 per share on the National Stock Exchange for the 60 trading days preceding the public announcement. The committee’s recommendation was unanimously approved. The IDC members listed in the disclosure are Mr. Nandkumar Kashinath Chodankar (Chairperson), Ms. Shilpa Vinodkumar Bhatia, Mr. Vijayanarayanan Mahadevan, and Mr. Deepak Rameshchandra Shah. The committee’s conclusion is framed as regulatory compliance-based, rather than a view on where the stock should trade.

Market price vs offer price: the gap the IDC flagged

Even while recommending the offer as fair under the regulations, the IDC flagged that market prices were higher than the offer price at the time referenced. It noted the closing market prices on July 17, 2026 of ₹482.50 on BSE and ₹483.50 on NSE. Both are materially above ₹299, the open offer price. This difference is relevant for shareholders who may prefer selling in the market rather than tendering. The IDC explicitly advised public shareholders to independently evaluate the company’s market performance and their own investment objectives before tendering shares. That line is important because an IDC recommendation is not the same as a directive to tender. In practice, shareholders often compare the offer price against the latest traded price, liquidity, taxes, and their holding horizon before deciding.

Tendering window and key process dates

The tendering period for the open offer is stated as July 28 to August 10, 2026. This window is when eligible public shareholders can tender their shares into the open offer, subject to the offer terms and any applicable procedural requirements. The disclosure positions the IDC recommendation as a formal step in the overall open offer process. Investors typically track the tendering period closely because it determines execution timing, settlement schedules, and the opportunity cost versus selling in the secondary market. The company’s communication also indicates that the recommendation is being shared as part of the SEBI SAST compliance framework.

Dividend update: final dividend approved for FY26

Separately, Bliss GVS Pharma held its 41st Annual General Meeting on July 15, 2026. At the meeting, shareholders approved the declaration of a final dividend of ₹1.00 per share for FY26. While the dividend is not directly linked to the open offer mechanics, it is a relevant shareholder return item that investors may consider alongside corporate actions. Dividend decisions can also affect near-term price behaviour around record dates and ex-dividend trading, depending on the company’s stated timelines and market conditions.

Credit ratings: ICRA places ratings on watch

The article also notes a ratings development from ICRA. ICRA placed Bliss GVS Pharma Limited’s ratings on “Watch with Developing Implications.” The disclosure cites rated facilities of 100.00 (long term) and 100.00 (short term), with ratings referenced as [ICRA]A- and [ICRA]A2+ on watch. ICRA’s note adds that the near-term impact on Bliss’ credit profile is expected to remain limited, as no material operational changes are envisaged over the next 8 to 12 months and no incremental debt is proposed to be added to Bliss’ balance sheet as part of the transaction. It also flagged monitorables such as leadership transition following the promoter’s exit and realisation of potential business synergies. ICRA stated it would resolve the rating watch once clarity emerges on ownership transition, completion of the transaction, and the actual credit impact.

Snapshot of key numbers cited in the disclosure

The market data shared alongside the open offer coverage includes a market capitalisation figure and standard valuation metrics. It also includes the stock’s cited trading price and previous close around July 21, 2026. These figures help frame the open offer price in the context of prevailing valuations, although the offer price itself is governed by SEBI SAST pricing rules.

What shareholders may weigh before tendering

The IDC’s advisory to shareholders is to evaluate market performance and personal investment objectives before tendering. With the cited market closes above the offer price, many investors may compare immediate liquidity in the secondary market versus the open offer route. Others may consider whether tendering aligns with their risk preferences and holding strategy, particularly given the open offer’s fixed price. The ICRA rating watch note also adds context that the transaction-related transition remains a monitorable, even if near-term operational disruption is not expected in the rating agency’s view. The disclosure also reflects that the open offer is being executed through a regulated process, with a named merchant banker acting as manager.

Conclusion

Bliss GVS Pharma’s independent directors have recommended Anupam Rasayan’s open offer for 26% at ₹299 per share, stating the price is fair and reasonable under SEBI SAST rules. The tendering period is scheduled from July 28 to August 10, 2026. The IDC has also highlighted that the stock’s cited market closing prices were higher than the offer price, and advised shareholders to make an independent decision. Investors are likely to track the tender window, further disclosures on the ownership transition, and ICRA’s eventual resolution of its rating watch once the transaction outcome becomes clearer.